In this issue:
ALCYONE shows improved OS and PFS with the addition of daratumumab to VMP in NDMM
Three-year CASTOR update confirms benefit of daratumumab-based therapy in RRMM
Augmented bendamustine/melphalan conditioning improves response to ASCT
Frailty a negative prognostic factor for outcome in ASCT
A simplified frailty score predicts outcome in transplant-ineligible MM patients
Real-world SEER database study analyses medication adherence factors
Fractures and survival in multiple myeloma
MRD-negativity predicts favourable outcomes in ND transplant-eligible MM
The first-in-human study of the pan- PIM kinase inhibitor PIM447 in RRMM
EZH2 overexpression in MM
Please login below to download this issue (PDF)